Psilocybin
News You Might Have Missed: Dec 5th 2022
The article News You Might Have Missed: Dec 5th 2022 was originally published on Microdose.
Welcome to the News You Might Have Missed, a weekly roundup…
The article News You Might Have Missed: Dec 5th 2022 was originally published on Microdose.
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Protests in Ottawa for Access to Psychedelic Medicine
Non-profit group TheraPsil has brought a group of patients and medical professionals across Canada to Ottawa to fight for medical access to psilocybin mushrooms.
The intent is to engage with policymakers and the public around well-established potential benefits of psilocybin for end-of-life anxiety, depression and PTSD. A protest was held at 1 pm on Nov 29th and 30th, 2022, at Parliament Hill in Ottawa.
DEA Increases Production Quotas for Psychedelics
The Drug Enforcement Administration (DEA) has released its production quotas for 2023, announcing an increase in the permitted quantity of psychedelic compounds manufactured for research purposes. This is good news, as the increase will make it that much easier for researchers to continue their work.
Numinus Wellness Reports Q4 2022 and Annual Results
“Fiscal 2022 was a pivotal year for Numinus, as we entered the US market with the transformational acquisition of Novamind, expanded our Ketamine-assisted Therapy offering across Canada, launched a formal practitioner training program, and unveiled a global rebranding of our company.” Payton Nyquvest, Founder and CEO.
- Q4 2022 revenues grew 643% year-over-year to $4.2 million
- Q4 2022 gross margin grew to 31.5%, generated $1.3 million of gross profit
- Completed acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapies
- Ended quarter with cash position of $33.0 million
New Study Shows Psychedelics Lowers Barriers to Higher Brain States
A new study shows that psychedelics lower the energy needed to reach higher levels of consciousness. A recent study conducted by Cornell University has shown that psychedelics might lower the energy threshold brain networks require in order to shift to different configurations. How is this possible? The theories and models surrounding such findings are going to be illustrated in this article, which also provides an outline of the results of the study.
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
psilocybin ketamine psychedelic therapy depression anxiety ptsd psychedelics novamind numinus wellness numinus research
-
Law & Regulation1 week ago
Relmada Therapeutics trims losses, slashes research costs
-
Psychedelics1 week ago
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
-
Psychedelics1 week ago
Numinus Wellness Submits Clinical Trial Application
-
Psychedelics1 week ago
Psyence Biomedical Ltd. Announces Results of Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
-
Psychedelics1 week ago
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
-
Psilocybin7 days ago
Indigenous Psilocybin Practices Around the World
-
Law & Regulation1 week ago
Gilgamesh secures $14M for ibogaine-like drug
-
Psychedelics1 week ago
Gilgamesh Receives Grant To Combat Opioid Dependency